相关实验视频
Updated: Jan 8, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
761
在没有痴呆症的日本老年人中对粉样蛋白PET披露的立即反应
Kenichiro Sato1,2,3, Yoshiki Niimi2,3, Ryoko Ihara4
1Department of Neuropathology Graduate School of Medicine The University of Tokyo Tokyo Japan.
Alzheimer's & dementia (New York, N. Y.)
|December 22, 2025
概括
在没有痴呆症的日本个体中,粉样蛋白PET的披露被很好地容忍,在粉样蛋白阳性参与者中,痛苦程度略有增加. 这些发现支持跨不同文化背景的结构化披露协议.
科学领域:
- 神经学 神经学
- 心理学 心理学 心理学
- 医疗成像医学成像
背景情况:
- 粉样PET对于早期阿尔茨海默病 (AD) 检测和治疗资格至关重要.
- 在北美和欧洲以外,关于粉样蛋白PET披露对心理影响的数据有限.
- 这项研究评估了在没有痴呆症的日本队列中直接的心理影响.
研究的目的:
- 为了评估粉样质正子发射断层扫描 (PET) 在日本人口中披露的心理影响.
- 评估痛苦,未来时间展望 (FTP) 和对AD后披露的担忧.
- 为了比较粉样蛋白PET阳性和粉样蛋白PET阴性个体之间的结果.
主要方法:
- 分析了来自日本630名认知正常或轻度认知障碍的参与者 (50-85岁) 的数据.
- 粉样蛋白PET阳性通过视觉读取或粉样蛋白≥12.
- 心理结果 (FTP,对AD的担忧,事件规模的影响) 在披露前和披露后被评估.
主要成果:
- 26%的参与者是粉样蛋白-PET阳性.
- 与PET阴性同龄人相比,PET阳性个体报告了更大的痛苦 (IES: 8vs3).
- 对阿尔茨海默病的担忧在PET阳性患者中增加 (+4.8%),但在PET阴性患者中减少 (-5.5%).
结论:
- 在这个日本队列中,amyloid PET的披露通常被很好地容忍,类似于西方的发现.
- 在PET阳性个体中观察到痛苦和担忧的适度增加.
- 结果支持跨文化披露协议的伦理可接受性,强调为有风险群体提供量身定制的咨询.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.亚洲的亚洲人亚洲人的亚洲人日本人 日本人 日本人 日本人粉胺PET是一种PET.轻度的认知障碍 轻度的认知障碍在临床前的临床前.心理上的痛苦 心理上的痛苦更多相关视频
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
11.0K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.9K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
01:22Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752